Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response

Lu Chen; Kenneth R Carson; Karl W Staser; Neha Mehta-Shah; András Schaffer; Ilana S Rosman; Amy Musiek

doi:10.1001/jamadermatol.2019.0369

Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response

JAMA Dermatol. 2019 Aug 1;155(8):968-971. doi: 10.1001/jamadermatol.2019.0369.

Authors

Lu Chen^{1

2}, Kenneth R Carson^{3

4

5}, Karl W Staser¹, Neha Mehta-Shah³, András Schaffer^{6

7}, Ilana S Rosman^{1

6}, Amy Musiek¹

Affiliations

¹ Division of Dermatology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.
² The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York.
³ Division of Medical Oncology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.
⁴ St Louis Veterans Health Administration Medical Center, St Louis, Missouri.
⁵ Flatiron Health Inc, New York, New York.
⁶ Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri.
⁷ Tallahassee Associates of Dermatology, Florida State University College of Medicine, Tallahassee, Florida.

Abstract

This case series report of mogamulizumab-associated cutaneous granulomatous drug eruption (CGDE) describes 12 patients with mycosis fungoides (MF) whose CGDE mimicked the MF but was followed by durable clinical MF response.